[{"address1": "The Goldyne Savad Institute of Gene Therapy", "address2": "Hadassah Hebrew University Medical Center", "city": "Jerusalem", "zip": "9112001", "country": "Israel", "phone": "972 2 674 3430", "fax": "972 2 643 0982", "website": "https://silexion.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.", "companyOfficers": [{"maxAge": 1, "name": "Ms. Mirit Horenshtein Hadar", "age": 39, "title": "EVP of Finance Affairs, CFO & Secretary", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 69977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mitchell  Shirvan M.B.A., Ph.D.", "age": 69, "title": "Chief Scientific & Development Officer", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 206800, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.94, "open": 2.01, "dayLow": 1.82, "dayHigh": 2.05, "regularMarketPreviousClose": 1.94, "regularMarketOpen": 2.01, "regularMarketDayLow": 1.82, "regularMarketDayHigh": 2.05, "beta": -0.111, "forwardPE": -3.0312502, "volume": 68120, "regularMarketVolume": 68120, "averageVolume": 4472380, "averageVolume10days": 138680, "averageDailyVolume10Day": 138680, "bid": 1.87, "ask": 1.99, "bidSize": 100, "askSize": 100, "marketCap": 3109994, "fiftyTwoWeekLow": 0.207, "fiftyTwoWeekHigh": 13.558, "fiftyDayAverage": 1.5342, "twoHundredDayAverage": 6.332275, "currency": "USD", "enterpriseValue": 16461319, "floatShares": 219739, "sharesOutstanding": 1603090, "sharesShort": 35842, "sharesShortPriorMonth": 9885, "sharesShortPreviousMonthDate": 1728950400, "dateShortInterest": 1731628800, "sharesPercentSharesOut": 0.0224, "heldPercentInsiders": 0.32575, "heldPercentInstitutions": 0.08151, "shortRatio": 0.23, "shortPercentOfFloat": 0.0308, "impliedSharesOutstanding": 1603090, "bookValue": 4.669, "priceToBook": 0.41550654, "lastFiscalYearEnd": 1388448000, "nextFiscalYearEnd": 1419984000, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -1355000, "trailingEps": -13.22, "forwardEps": -0.64, "enterpriseToEbitda": -12.149, "52WeekChange": -0.82395643, "SandP52WeekChange": 0.24176979, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SLXN", "underlyingSymbol": "SLXN", "shortName": "Silexion Therapeutics Corp", "longName": "Silexion Therapeutics Corp", "firstTradeDateEpochUtc": 1617802200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "af8f42f8-a6ed-3783-8905-4b79cec71d33", "messageBoardId": "finmb_134350646", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.94, "targetHighPrice": 9.0, "targetLowPrice": 9.0, "targetMeanPrice": 9.0, "targetMedianPrice": 9.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 2781000, "totalCashPerShare": 11.102, "ebitda": -1355000, "totalDebt": 144000, "quickRatio": 3.639, "currentRatio": 3.851, "debtToEquity": 8.944, "returnOnAssets": -0.62134, "returnOnEquity": -1.16659, "freeCashflow": -305625, "operatingCashflow": -794000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]